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Familial amyloid polyneuropathy (FAP) is characterized by deposition of mutated transthyretin (TTR) in the
peripheral nervous system. Prior to amyloid fibrils, nonfibrillar TTR aggregates are deposited inducing
oxidative stress with increased nitration (3-NT). As the major source of TTR is the liver, liver transplantation (LT)
is used to halt FAP. Given the shortage of liver donors, domino LT (DLT) using FAP livers is performed. The
correlation between TTR deposition in the skin and nerve was tested in biopsies from normal individuals,
asymptomatic carriers (FAP 0) and FAP patients; in FAP 0, nonfibrillar TTR was observed both in the skin and
nerve in the same individuals; in patients, amyloid was detected in both tissues. The occurrence of amyloidosis
in recipients of FAP livers was evaluated 1–7 years after DLT: TTR deposition occurred in the skin 3 years after
transplantation either as amyloid or aggregates; in one of the recipients, fibrillar TTR was present in the
epineurium 6 years after DLT. Deposits were scarce and 3-NT immunostaining was irrelevant. Nerve biopsies
from DLT recipients had no FAP-related neuropathy. Our findings suggest that TTR amyloid formation occurs
faster than predicted and that TTR of liver origin can cross the blood-nerve barrier. Recipients of FAP livers
should be under surveillance for TTR deposition and tissue damage.
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Familial amyloid polyneuropathy (FAP) is a neuro-
degenerative autosomal dominant disorder charac-
terized by the systemic extracellular deposition of
mutated transthyretin (TTR) amyloid fibrils
throughout the connective tissue, particularly affect-
ing the peripheral nervous system (PNS).1 In the
PNS of FAP patients, fibrils occur especially in the
endoneurium, leading to axonal loss and neuro-
degeneration.2,3 The onset of clinical symptoms
generally occurs before the age of 40 years and
consists of progressive sensory, motor and auto-
nomic polyneuropathy. Sensory impairment is
among the first symptoms, with pain and tempera-
ture sensations being the most severely affected;1
motor involvement occurs later causing wasting and
weakness. The majority of FAP patients have early
autonomic nervous system involvement. Untreated,
the disease relentlessly progresses causing severe
disability and ultimately death.
Among the point mutations in TTR that promote
amyloidogenesis, the most common is a substitution
of Val for Met at position 30 of the protein.4 The
pathway of fibril formation and the mechanisms
through which neurodegeneration occurs in FAP are
still not fully understood. Cytotoxicity of early
nonfibrillar TTR aggregates has been previously
found in asymptomatic FAP patients (FAP 0);5,6
despite the absence of amyloid fibrils, FAP 0 nerves
show signs of neuronal stress presenting increased
expression of proinflammatory cytokines, oxidative
stress-related molecules and apoptosis.5,6
As approximately 90% of plasma TTR is pro-
duced by the liver,7 liver transplantation (LT) has
been used as a means of abolishing the production of
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most of the amyloidogenic variant TTR. In 1990 the
first LT for FAP was performed8 and to date, this
procedure is the only treatment that appears to halt
the progression of the disease.9–11 In spite of the
progression of the disease being halted, the irrever-
sibility of some neurological lesions seems to
persist12 although in some cases, symptomatic,
autonomic and sensorimotor improvements, namely
improved general well-being, walking ability and
regain of bladder and bowel functions were re-
ported.13–16 It is, however, generally considered that
patients should be transplanted as soon as the
symptoms start.17,18 The long-term outcome of LT
as a therapy for FAP remains unknown.
As the shortage of donor livers has been the rate-
limiting factor in the expansion of LT, domino liver
transplantation (DLT), which was first reported in
Portugal in 1995,19 has been performed worldwide
and allows a donor organ to be used for a subsequent
graft in a second liver recipient; in this procedure,
FAP patients receive and sequentially donate grafts
to other recipients. DLT involves specific ethical and
technical problems, the most important of which is
the graft of a liver producing a pathogenic protein
into a recipient individual. Owing to the lack of
knowledge relative to the fibrillogenesis pathway
and kinetics of deposition of TTR amyloid, the
possibility of de novo amyloidosis in recipients of
livers from FAP patients remains a serious concern.
In most cases, functionally normal livers (excluding
the production of mutated TTR) from FAP patients
have been used as a source of organs mainly for
selected recipients, particularly older subjects in
whom the event of de novo amyloidosis is unlikely.
In Brazil, recipients of FAP livers have been
followed for clinical and electroneuromyographic
signs of FAP and for de novo amyloid deposition in
the gut, and no signs of de novo amyloid deposits
were observed after a mean follow-up of 24
months.20
The purpose of this work was to study the
presence of de novo amyloid deposition and toxicity
in the skin and nerve of recipients of FAP livers up
to 7 years after DLT.
Material and methods
Participants
Skin biopsies from normal individuals (n¼ 5) and
sural nerve and skin biopsies from asymptomatic
carriers (FAP 0, n¼ 10) and FAP patients in late
stages of disease progression (n¼ 8) were available
at the Hospital Geral de Santo Anto´nio, Porto,
Portugal, since this material was obtained as part
of the clinical diagnosis and evaluation of poly-
neuropathy, prior to the current use of less invasive
methods. Initial characterization of nerve biopsies
included morphometric studies of nerve fiber
density and abundance of amyloid deposits.
DLT, as well as biopsy collection from LT patients,
are protocols approved by the Ethics Committee of
the Transplantation Department, University Hospi-
tals of Coimbra, Portugal and include informed
consent; FAP liver donors had typical clinical
symptoms,1 a family history of FAP, which included
the fact that either their mother or father was
deceased with FAP with an average of 50 years of
age, and were carriers of the TTR Val30Met variant
(demonstration of the TTR Val30Met mutation,
performed by DNA analysis, is an international
requirement for undergoing liver transplantation). A
total of 15 FAP patients (four males, mean age 36
(range 31–44) years and 11 females, mean age 35
(range 28–55) years) were subjected to LT from 1995
to 2003. The livers from the FAP patients were
sequentially transplanted into 13 male and 2 female
recipients (mean age 53 (range 46–61) years) either
with chronic liver disease (n¼ 11) or with liver
tumors (n¼ 4). DLT recipients had no clinical
history or clinical signs of FAP. Four DLT recipients
underwent a skin biopsy before the transplant; skin
biopsies were collected either up to 2 years after DLT
(n¼ 6), between 2 and 5 years (n¼ 6) or 6 years after
DLT (n¼ 3). Nerve biopsies were performed in
selected recipients who were subjected to DLT for
more 5 years. Evaluation of de novo TTR deposition
was performed by TTR immunohistochemistry and
Congo red staining.21 Control skin biopsies were
performed in FAP patients (n¼ 5) and non-FAP
patients (n¼ 4) submitted to conventional LT 3 years
before.
Morphometry
Morphometric studies were perfomed on sural nerve
biopsy tissue fixed in gluteraldehyde (1.25%). in
0.1 M cacodylate buffer pH 7.4, postfixed in osmium
tetroxide, and embedded in Epon. Quantitation of
myelinated fibers (MF) in semithin sections was
performed in an area of at least 0.1 mm2 at a
magnification of  1000. Myelinated fibers were
counted, their diameters were measured and the
density was calculated. Myelinated fibers with a
diameter o6 mm were scored as small and fibers
with a diameter Z6mm were scored as large.
Unmyelinated fibers (UF) were counted from thin
sections in an area of at least 0.005 mm2, and their
densities were calculated. A scoring system of
patient material was based on the morphometry of
MFs and UFs: FAP 0 (n¼ 5), no reduction in the
number of fibers (MFs from 11 000 to 7000 fibers/
mm2; UFs from 80 000 to 30 000 fibers/mm2); FAP 1
(n¼ 4), discrete reduction (MFs varied between
o7000 and 2000 fibers/mm2; UFs varied between
o30 000 and 4000 fibers/mm2); FAP 2 (n¼ 4), evi-
dent reduction (MFso2000 and 1000 fibers/mm2;
UFso4000 fibers/mm2); and FAP 3 (n¼ 3), severe
reduction (MFso1000 fibers/mm2; UFs absent).
Standard values for control nerves ranged from
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11 000 to 7000 fibers/mm2 for MFs and from 80 000
to 30 000 fibers/mm2 for UFs.
Immunohistochemistry
For immunohistochemistry, paraffin sections were
deparaffinated, dehydrated in a modified alcohol
series and incubated in blocking buffer (1% bovine
serum albumin, BSA, and 4% horse serum in PBS)
for 30 min at 371C in a moist chamber. Incubation
with primary antibody at the appropriate dilution in
blocking buffer was performed overnight at 41C.
The primary antibodies used were: mouse mono-
clonal anti-TTR Mab39-4422 and anti-3 nitrotyrosine
(Chemicon, 1:1000). Antigen visualization was
performed with the biotin–extravidin–peroxidase
kit (Sigma), using 3-amino-9-ethyl carbazole (Sigma)
as a substrate. On parallel control sections, primary
antibody was replaced by blocking buffer. A series of
five adjacent slides separated from each other by
25 mm was examined for each individual for TTR
IHC. Semiquantitative immunohistochemistry (SQ-
IHC) analysis was performed using the Universal
Imaging system (NIH) that performs automated
particle analysis in a measured area. The results
shown represent % occupied area7s.d.
Electron Microscopy and Immunogold TTR Labeling
Small skin pieces were fixed in 2.5% gluteraldehyde
in PBS for 2 h and subsequently washed in PBS.
Semithin sections (1 mm) were cut from epon-
embedded blocks and stained with toluidine blue.
Ultrathin sections (500 A˚) were cut in an ultratome
(LK Brumma Nova), mounted on nickel grids,
blocked with 1% BSA in PBS for 30 min and
incubated with rabbit anti-human TTR (DAKO)
diluted 1:100 in 1% BSA for 1 h at room tempera-
ture. Control grids were incubated with preabsorbed
anti-human TTR. Incubation with anti-rabbit im-
munoglobulins coupled to 10 nm gold particles
(Amersham) diluted 1:15 in 1% BSA was performed
for 30 min at room temperature. Grids were then
stained with uranyl acetate (3 min) and lead citrate
(2 min).
Clinical Evaluation of Neuropathy
Clinical examination for neuropathic assessment
was performed by touch in both feet using a 10 g
monofilament as the mechanical stimulus and hot
and cold rods as the thermal stimulus; reflexes were
tested with a tendon hammer.
Electromyography
Needle electromyography (EMG) was performed
with a concentric needle electrode. Nerve conduc-
tion studies were conducted with a limb tempera-
ture above 321C. Motor responses were recorded
with surface electrodes (belly-tendon montage); the
radial (wrist-digit I) and median (wrist-digit III)
nerves sensory responses were recorded antidromi-
cally through near-nerve needle electrodes after
superficial stimulation.
Results
Skin Biopsy as a Valuable Tool for the Evaluation of
TTR Deposition and Cytotoxicity
Detection of amyloid deposits in FAP nerve biopsies
is considered the gold standard for clinical evalua-
tion of amyloid neuropathy. We assessed whether
skin biopsies, a minimally invasive procedure, are a
sensitive tool to evaluate TTR deposition in FAP.
TTR immunohistochemistry and CR staining were
performed in the skin of normal individuals (n¼ 5),
FAP 0 (asymptomatic) individuals with nonfibrillar
TTR deposition in the nerve (n¼ 9) and FAP
patients in latter stages of disease progression (FAP
2 and FAP 3, n¼ 8). In normal individuals, TTR was
absent and CR staining was negative (Table in
Figure 1); in seven out of nine FAP 0 individuals,
TTR was deposited in the skin only as nonfibrillar
material, negative for CR staining (Table in Figure 1),
similar to what was detected on their sural nerve
biopsies (the same cases as published in Sousa
et al6). Skin biopsies from two FAP 0 individuals
showed the presence of TTR amyloid fibrils
(Table in Figure 1) suggesting that in the skin,
amyloid can be detected early and that nonfibrillar
TTR deposition constitutes a presymptomatic test.
All but two of the eight observed skin biopsies from
FAP patients with proven amyloid in the nerve
presented TTR deposition in the form of amyloid
fibrils (Table in Figure 1) with the characteristic
involvement of the lower reticular dermis, sweat
glands, hair erector muscle and blood vessels.
Curiously, one of these cases did not show evidence
of TTR deposition despite being symptomatic for 3
years (Table in Figure 1). These data suggest that in
the majority of the FAP patients studied, skin
biopsies represent a valuable tool and relate with
deposition in the nerve.
We have previously shown that nonfibrillar TTR
deposition in the nerve is accompanied by oxidative
stress in this tissue as detected by an increase in 3-
nitrotyrosine (3-NT) staining.6 To test if similar
mechanisms were occurring in the skin, we per-
formed SQ-IHC for 3-NT in skin biopsies from
normal individuals (n¼ 5), FAP 0 patients (n¼ 9)
and FAP patients in later stages of disease progres-
sion (FAP 2 and 3, n¼ 8). Similar to what was
observed in the nerve, there was an approximately
three-fold increase in 3-NT epitopes in skins with
TTR aggregates, when compared to normal skins
(Figure 1, histogram). Interestingly, 3-NT staining
was higher when TTR was deposited as nonfibrillar
aggregates than when the protein was present in the
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Figure 1 Table: correlation between TTR deposition in the nerve and skin of FAP patients in different stages of disease progression.
Histogram: quantitation of immunohistochemical images corresponding to 3-NT immunostaining in control individuals and FAP
patients in different stages of disease progression. Data are represented as percent occupied area7s.d. (*Po0.005).
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form of amyloid fibrils (Figure 1, histogram). These
results suggest that similar to what we have
described in the nerve, TTR deposition in the skin
of FAP patients is accompanied by oxidative stress.
De Novo Amyloidosis in Recipients of DLT
Given the fact that TTR deposition in the skin seems
to occur early in FAP and to correlate with
deposition in the nerve, we analyzed skin biopsies
from recipients of FAP livers 1–7 years after DLT.
Analysis of skin biopsies performed either prior to
DLT (n¼ 4) or in non-FAP individuals undergoing
conventional LT (n¼ 4) did not show deposition
of TTR (data not shown). FAP patients submitted
to conventional LT (n¼ 5) still presented the
characteristic TTR amyloid deposition in the
skin (Figure 2a, TF). Up to 2 years after DLT, none
of the examined skins from recipient individuals
presented TTR deposition (Table 1). Between 3–5
years after DLT, deposition was variable and did not
correlate with time of transplant; among the two
cases of recipients who underwent DLT in the
preceding 5 years, one had no deposition whereas
in the other amyloid was detected (Table 1). The
remaining individuals (4–5 years after DLT) showed
only nonfibrillar TTR deposition. Six to seven years
after DLT, amyloid deposition was evidenced in all
the cases (Table 1). The amount of deposited
material was variable among recipients being gen-
erally scarce both in nonfibrillar and fibrillar forms,
as demonstrated in Figure 2a (TTR staining, arrows,
first two rows, DLT /þ and DLT þ /þ ). One of the
recipients in whom the skin biopsy was performed 6
years after DLT presented TTR deposition both in
the fibrillar and nonfibrillar form (Figure 2a, third
row, DLT þ /þ , arrows) comparable to the char-
acteristic TTR deposition in the skin of FAP patients
(Figure 2a, bottom row, TF). The presence of TTR
amyloid fibrils in the skin of this DLT recipient was
further confirmed by TTR immunoelectronmicro-
scopy (Figure 2b, arrows); DLT recipients who did
not present TTR immunoreactivity were also nega-
tive by immunoelectronmicroscopy (data not
shown). Given the fact that the amount of deposited
TTR was generally very scarce, dermatological
symptoms were absent.
Despite the low amounts of TTR deposition in the
skin of DLT recipients (excluding the sole DLT
recipient where deposits were comparable to the
ones found in FAP), we addressed the possibility
that similar to what is observed in FAP patients,
TTR deposits might be leading to oxidative stress.
3-NT IHC in skin biopsies from DLT recipients with
fibrillar (DLT þ /þ ) and nonfibrillar TTR deposi-
tion (DLT /þ ), had not increased relative to
normal skin biopsies and to non-FAP individuals
submitted to conventional LT (Figure 2a, right
panels and Figure 2c). FAP patients who underwent
conventional LT still presented an increase in 3-NT
epitopes in sites related to TTR deposition (Figure
2a, bottom row) typical of nontransplanted FAP
patients. In conclusion, the amount of TTR deposi-
tion in the majority of the DLT recipients does not
seem sufficient to promote an increase in oxidative
stress in target organs.
Nerve Pathology in Recipients of DLT
As DLT recipients presented TTR deposition in the
skin, the possibility that TTR deposits existed in the
nerve remained to be addressed. Sural nerve
biopsies from six recipients of FAP livers who
underwent DLT in the preceding 5–7 years were
performed. Five of the nerve biopsies had no TTR
deposits (Table 2); however, one of the nerve
biopsies performed 6 years after DLT disclosed a
small deposit of TTR amyloid fibrils in the epineu-
rium (Table 2, Figure 3, arrows). This TTR positive
nerve did not reveal any 3-NT immunostaining
(Figure 3), similar to what happens in normal
nerves, therefore suggesting that the amount of
TTR deposition is not sufficient to produce oxida-
tive stress. Morphometry of myelinated and unmye-
linated fibers was performed in these nerve biopsies;
a minor reduction in the density of myelinated
fibers was observed in the majority of the cases, with
a more pronounced loss of small diameter fibers in
some cases and large diameter fibers in others (Table
2). In all the examined nerve biopsies, the density of
unmyelinated fibers was within the normal range for
control nerves. The reduction in the number of
myelinated fibers is probably not due to the
presence of mutated TTR as the majority of the
nerves do not show TTR deposition; furthermore,
one of the major features of neurodegeneration in
FAP consists of the primary loss of unmyelinated
rather than myelinated fibers. Clinical examination
for putative neuropathic manifestations was per-
formed, but all the DLT recipients presented normal
sensory abilities and motor findings such as distal
weakness were not present. To further evaluate
possible neuropathological changes related with
DLT, EMG was performed 5–7 years after transplant.
The only DLT recipient who showed TTR deposition
Table 1 Deposition of TTR in skin biopsies performed in
recipients of FAP livers 1–7 years after DLT
Years after DLT TTR/CR
1 (n¼ 3)  
2 (n¼ 3)  
3 (n¼ 1) + +
4 (n¼ 2) + 
5 (n¼ 1)  
5 (n¼ 1) + 
5 (n¼ 1) + +
6 (n¼ 2) + +
7 (n¼ 1) + +
TTR deposition in recipients of FAP livers
MM Sousa et al
869
Laboratory Investigation (2004) 84, 865–873
TTR deposition in recipients of FAP livers
MM Sousa et al
870
Laboratory Investigation (2004) 84, 865–873
in the nerve did not present any signs of polyneuro-
pathy (Table 2), therefore suggesting that the
observed deposition of TTR amyloid fibrils in the
epineurium was not sufficient to promote neuro-
pathic changes. However, two of the DLT recipients
showed signs of polyneuropathy that developed
post-transplantation (Table 2). One should however
note that in these individuals no TTR deposition
was found in the nerve highly suggestive that the
observed polyneuropathy was probably caused by
other pathologies exhibited by these patients,
namely diabetes and alcoholism, in the latter case
due to the fact that alcohol intake persisted post-
transplantation.
Discussion
In this report, we show that de novo amyloidosis
occurs in the skin and nerve of recipients of FAP
livers after DLT. Despite the occurrence of de novo
amyloidosis in DLT recipients, the amount of
deposited TTR in the majority of the observed cases,
both in the skin and in the nerve, was very scarce.
Moreover, sites related to TTR deposition did not
display signs of oxidative stress probably due to the
reduced amount of deposited TTR. At this point,
TTR deposits in the DLT recipients do not seem to
produce oxidative stress, dermatologic symptoms
and FAP-related nerve fiber loss but the long-term
effect of DLT remains unknown and one should not
rule out the possibility that FAP may develop in
long-living DLT recipients.
We started by demonstrating that skin biopsies are
a suitable material for the evaluation of TTR
deposition, correlating well with TTR deposition
in sural nerves. Therefore, the initial assessment of
the presence of TTR deposits in skin biopsies from
DLT individuals constitutes a valuable tool to assess
the possible deposition and deleterious effects of
TTR in the nerve after DLT. The DLT recipients
reported here showed deposition of TTR in the skin
as early as 3 years after DLT, and in the nerve 6 years
after DLT. Dermatological symptoms in FAP have
occasionally been documented as a consequence of
TTR deposition in the skin; multiple atrophic scars
Figure 2 (a) Evaluation of TTR deposition in the skin of recipients of FAP livers by CR staining (left column) and TTR
immunohistochemistry (middle column) and the presence of oxidative stress by 3-NT immunohistochemistry (right column). DLT
/þ , CR-negative/TTR-positive recipient; DLT þ /þ CR-positive/TTR-positive recipient; TF, FAP patient submitted to conventional LT.
In DLT recipients, the amount of deposited TTR varied, being generally scarce, and 3-NT had not increased relative to normal skin
biopsies; only one case showed TTR deposition comparable to FAP patients. TF presented TTR deposition and 3-NT staining
characteristic of FAP patients. (b) Anti-TTR immunoelectronmicroscopy of a skin biopsy performed 3 years after DLT presenting TTR
amyloid fibrils. (c) Quantitation of immunohistochemical images corresponding to 3-NT immunostaining in FAP 0 carriers and in
recipients of FAP livers (DLT). Data are represented as percent occupied area7s.d. (*Po 0.005).
Table 2 Deposition of TTR and morphometric study of nerve biopsies from recipients of FAP livers and EMG evaluation 5–7 years after
DLT
Years post-DLT Pathology prior DLT TTR/CR MF/mm2 + MF lost UF/mm2 EMG prior DLT EMG at the time of biopsy
5 Hepatitis + diabetes   5368 Large 39 738 No signs of PNP Sensory axonal NP
5 Hepatitis   7331 Large 83 136 NA NA
5 Hepato carcinoma   3571 Small 88 330 NA No signs of PNP
7 Hepato carcinoma   3525 Small 48 340 NA No signs of PNP
6 Alcoholic cirrhosis   4691 Small 52 951 No signs of PNP Sensory-motor changes
6 Neuroendocrine tumor + + 4976 Small 44 503 No signs of PNP No signs of PNP
MF, myelinated fiber; UF, unmyelinated fiber; +, diameter; PNP, polyneuropathy; NP, neuropathy; NA, not available.
Figure 3 Evaluation of TTR deposition in a nerve biopsy performed 6 years after DLT assessed by CR staining (left panel) and TTR
immunohistochemistry (middle panel); oxidative stress evaluated by 3-NT staining (right panel). TTR amyloid fibrils were present in the
epineurium without signs of oxidative stress.
TTR deposition in recipients of FAP livers
MM Sousa et al
871
Laboratory Investigation (2004) 84, 865–873
and ulcers on the limbs have been observed in some
FAP patients;23 nodular cutaneous amyloidosis in a
TTR Tyr114His FAP patient has also been de-
scribed.24 However, these occasional dermatological
symptoms are only present in the latest stages of
disease progression. It should be stressed that in the
DLT recipients reported here, the amount of depos-
ited TTR was generally very scarce and therefore
dermatological symptoms were not to be expected.
A previous study performed in Brazilian recipients
of FAP livers did not show any de novo amyloidosis
in the gut after a mean follow-up of 24 months
probably due to the short time of analysis.
In the TTR Val30Met FAP-associated mutation,
the onset of clinical symptoms occurs during
adulthood, generally before age 40 years and is fatal
in about 10–20 years. The predicted kinetics of
amyloid formation is therefore slow and allowed the
assumption that DLT recipients would probably not
develop TTR deposits shortly after transplant. In the
case of the skin, it is possible that aggregated or even
fibrillar TTR exists in young asymptomatic carriers
prior to major protein deposition in the peripheral
nervous system and the occurrence of the first
clinical symptoms. In fact, we show that in most
asymptomatic TTR Val30Met carriers, TTR is de-
posited as nonfibrillar aggregates in the skin and in
some instances already in the form of amyloid
fibrils, reinforcing the idea that skin involvement
might represent an early event in the course of the
disease.
The fact that recipients of FAP livers show skin
TTR deposition as early as 3 years after DLT lead us
to raise additionally the possibility that the fibrillo-
genesis pathway is accelerated in adults either due
to the enhancement of mechanisms involved in
amyloid formation or due to the downregulation of
inhibitory pathways. Given these assumptions,
children carrying amyloidogenic-mutated TTR
might not show deposition of the protein until
adulthood; however, this hypothesis is difficult to
test since molecular diagnosis is ethically not
possible to perform in children. In asymptomatic
TTR Val30Met carriers, TTR is generally present in
the nerve in the form of nonfibrillar aggregates, in
some cases many years prior to the occurrence of
first symptoms.6 In one of the DLT recipients whom
we report here, TTR amyloid fibrils were present in
the nerve six years after transplant favoring the
hypothesis that the fibrillogenesis pathway may be
preferentially triggered in adults. Organ-specific
amyloidogenesis may also be increased upon the
process of a transplant; in FAP patients who under-
went to conventional LT, although the production of
the amyloidogenic-mutated TTR is stopped, cardiac
amyloidosis can be exacerbated, probably due to
enhanced deposition of wild-type TTR on a tem-
plate of amyloid derived from variant TTR.25,26
The two major sites of TTR synthesis are the liver
and the choroid plexus of the brain that are
respectively, the sources of TTR found in the plasma
and in the cerebrospinal fluid (CSF).7 Therefore, the
deposited TTR in the PNS of FAP patients may
derive from the plasma pool and/or from the CSF
pool of the protein. Our report of de novo TTR
amyloidosis in recipients of FAP livers demon-
strates, however, that in individuals where the liver
is the sole source of mutated TTR, the protein is able
to deposit in the connective tissue of the epineurium
and skin, suggesting that the plasma pool of the
protein is sufficient for PNS involvement in FAP. In
the nerve, TTR deposition originating from the
plasma pool of the protein is probably due to the
permeability of the blood-nerve barrier that is
effective in slowing but not preventing the entry of
TTR into the nerve. One should, however, note that
the typical feature of amyloid deposition in the PNS
of FAP patients is the presence of amyloid fibrils
primarily in the endoneurium. However, the DLT
recipient reported here with fibrillar TTR in the
nerve showed deposition only in the epineurium,
which is generally less affected in typical FAP cases.
Therefore, at this point, one cannot exclude that in
FAP patients the source of TTR fibrils in the
endoneurial space is the CSF pool of the protein.
In FAP nerves, a primary loss of unmyelinated
nerve fibers occurs whereas large myelinated fibers
are only affected in the latest stages of disease
progression. In contrast, we observed that in the case
of nerves from recipients of FAP livers, the number
of unmyelinated fibers is normal and that a minor
reduction only occurs in myelinated fibers, without
being associated with clinical manifestations. This
observation suggested that the morphometric
changes were not related to FAP but were most
probably the consequence of other pathologies
causing sensory axonopathy, such as diabetes and
alcoholism, which were part of the clinical history
of some of these individuals. In agreement with this
hypothesis, the DLT recipients in whom polyneuro-
pathy developed after liver transplantation had no
signs of TTR deposition in the nerve, therefore
excluding the possibility of axonopathy caused by
TTR deposits. In FAP it has been hypothesized that
the loss of sensory and autonomic neurons may
function as the pathological background for the
preferential degeneration of unmyelinated and
small myelinated fibers.27 Sural nerve biopsies, on
which most of the pathological analysis in FAP has
been performed,28 represent a restricted portion of
the PNS, and it is clearly possible that amyloid
deposits in ganglia, or more proximally in nerve
trunks, might be responsible for distal nerve fiber
loss. In the case of DLT recipients, the fact that
the number of unmyelinated fibers is preserved
relative to control individuals makes it unlikely that
major TTR deposition occurs in the ganglia. It is
worth noting the fact that TTR deposition in the
epineurium in one of the DLT recipients was not
sufficient to promote FAP-related neurodegenera-
tion, as no evidence of polyneuropathy was
observed by EMG.
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In conclusion, DLT using FAP livers should
continue to be considered an experimental proce-
dure under careful surveillance, and recipients of
FAP livers should be followed up using an extensive
neurological and pathological examination.
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